Loading...
Publication
A consciencialização dos profissionais de saúde para o diagnóstico das doenças raras: o papel da indústria farmacêutica
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1785 | 406.21 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Existem mais de 6000 doenças raras, contudo o seu diagnóstico por parte dos profissionais de saúde é complexo, lento e tardio, fruto de uma formação pré e pós-graduada voltada para as patologias comuns. Como adquirem os clínicos uma maior consciência para o diagnóstico das doenças raras? São proactivos ou reativos? Quais os agentes de mudança? As universidades, instituições do SNS e sociedades médicas? A indústria farmacêutica, na procura de uma maior identificação dos doentes que necessitam das terapêuticas que promovem? Foi possível aferir a opinião de profissionais de saúde e da indústria farmacêutica, e com isso concluir que a indústria, talvez motivada pelos seus legítimos interesses comerciais, é o combustível e motor de uma série de atividades diretas e indiretas de formação para as doenças raras.
There are more than 6,000 rare diseases, but their diagnosis by health professionals is complex, slow, and delayed, because of pre- and post-graduate training focused on common pathologies. How do clinicians become more aware of diagnosing rare diseases? Are they proactive or reactive? Who are the agents of change? Universities, NHS institutions and medical societies? The pharmaceutical industry, seeking to better identify patients who need the therapies they promote? It was possible to gauge the opinion of health professionals and the pharmaceutical industry, and thus conclude that the industry, perhaps motivated by its legitimate commercial interests, is the fuel and driving force behind a series of direct and indirect training activities for rare diseases.
There are more than 6,000 rare diseases, but their diagnosis by health professionals is complex, slow, and delayed, because of pre- and post-graduate training focused on common pathologies. How do clinicians become more aware of diagnosing rare diseases? Are they proactive or reactive? Who are the agents of change? Universities, NHS institutions and medical societies? The pharmaceutical industry, seeking to better identify patients who need the therapies they promote? It was possible to gauge the opinion of health professionals and the pharmaceutical industry, and thus conclude that the industry, perhaps motivated by its legitimate commercial interests, is the fuel and driving force behind a series of direct and indirect training activities for rare diseases.
Description
Projeto de Graduação apresentado à Universidade Fernando Pessoa como parte dos requisitos para obtenção do grau de Licenciado em Ciências da Comunicação
Keywords
Doenças raras Formação Diagnóstico Profissionais de saúde Indústria farmacêutica Rare diseases Training Diagnosis Health professionals Pharmaceutical industry